Low-dose methotrexate in rheumatic diseases-Efficacy, side effects, and risk factors for side effects

Seminars in Arthritis and Rheumatism

Volumn 23, Issue 5, 1994, Pages 310-327

  Schnabel, Armin ^a   Gross, Wolfgang L ^a  

^a NONE

Author keywords

Methotrexate; rheumatic diseases; risk factors; toxicity

Indexed keywords

ALCOHOL; AMINOPHENAZONE; ANTIHYPERTENSIVE AGENT; ANTIMALARIAL AGENT; AURANOFIN; AUROTHIOMALATE; AZATHIOPRINE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CORTICOSTEROID; COTRIMOXAZOLE; CREATININE; FOLIC ACID; GOLD; HYDROXYCHLOROQUINE; LIVER ENZYME; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PHENYTOIN; PROBENECID; SALAZOSULFAPYRIDINE; SALICYLIC ACID DERIVATIVE; SULFONAMIDE; TETRACYCLINE DERIVATIVE;

ANKYLOSING SPONDYLITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOPENIA; DERMATOMYOSITIS; DOUBLE BLIND PROCEDURE; FELTY SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; JUVENILE RHEUMATOID ARTHRITIS; LIVER TOXICITY; PNEUMONIA; POLYMYOSITIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; REITER SYNDROME; REVIEW; RHEUMATIC DISEASE; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIVER CIRRHOSIS; LUNG DISEASES; METHOTREXATE; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; VASCULAR DISEASES;

EID: 0028226403     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/0049-0172(94)90027-2     Document Type: Article

References (173)

1. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial
2. Efficacy of low-dose methotrexate in rheumatoid arthritis
3. A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis
4. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study
5. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis
6. 24 week double-blind study of methotrexate in rheumatoid arthritis
7. Lowdose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double-blind trial
8. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis
9. Randomised study of methotrexate vs. gold sodium thiomalate in patients with active rheumatoid arthritis
10. Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis
11. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis
12. Comparative controlled trial of low-dose weekly methotrexate versus azathioprine in rheumatoid arthritis: 3-year prospective study
13. A double-blind controlled trial of azathioprine and methotrexate in the treatment of rheumatoid arthritis
14. Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A twenty-four-week controlled clinical trial
15. The comparative efficacy and toxicity of second-line drugs for rheumatoid arthritis
16. Use of shortterm efficacy/toxicity tradeoffs to second-line drugs in rheumatoid arthritis
17. The Effect of Local Heat and Cold Therapy on the Intraarticular and Skin Surface Temperature of the Knee
18. The efficacy and toxicity of a constant low dose of methotrexate as a treatment for intractable rheumatoid arthritis: An open prospective study
19. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis
20. Methotrexate therapy in rheumatoid arthritis: 2-year retrospective followup study
21. Toxicity of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis
22. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: A 14-year prospective evaluation of 1017 consecutive starts
23. Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment
24. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis
25. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis
26. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis
27. Followup study of chrysotherapy
28. Retardation of radiologic progression in rheumatoid arthritis with methotrexate therapy
29. A long-term prospective study of the use of methotrexate in rheumatoid arthritis
30. The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate to auranofin
31. Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis. A randomized, double-blind study
32. Methotrexate treatment in rheumatoid arthritis: Effects on radiological progression
33. Radiologic progression during intramuscular methotrexate treatment of rheumatoid arthritis
34. Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: Toxicity, efficacy and radiological progression
35. Methotrexate treatment of Felty's syndrome
36. Treatment of Felty's syndrome with low-dose oral methotrexate
37. Felty's syndrome: Response to low dose oral melhotrexate
38. Treatment of Felty's syndrome with intravenous methotrexate
39. Reversal of neutropenia with methotrexate treatment in patients with Felty's syndrome
40. Methotrexate treatment of Felty's syndrome
41. Worsening of Felty's syndrome with methotrexate
42. Adult Still's disease. Evolution of a clinical syndrome and diagnosis, treatment, and follow-up of 17 patients
43. Low dose methotrexate for Still's disease in adults
44. Coexistence of adult onset Stil's disease and polymyositis with rhabdomyolysis successfully treated with methotrexate and corticosteroids
45. Low dose methotrexate treatment in adult Still's disease
46. Fever in adult onset Still's disease. Response to methotrexate
47. Immunosuppressive Therapie des adulten M
48. Low-dose methotrexate therapy for cutaneous vasculitis of rheumatoid arthritis
49. Methotrexate in the treatment of vasculitic cutaneous ulceration in rheumatoid arthritis
50. Pulse methotrexate therapy for intractable rheumatoid cutaneous ulcers
51. Oral methotrexate therapy for chronic rheumatoid arthritis ulcerations
52. Accelerated nodulosis and vasculitis during methotrexate therapy for rheumatoid arthritis
53. Accelerated nodulosis during low dose methotrexate therapy for rheumatoid arthritis. An analysis of ten cases
54. Effects of second line drugs on progression or regression of subcutaneous rheumatoid nodules
55. Methotrexate therapy in psoriatic arthritis
56. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis
57. The Calcium-sensitive Cells of the Pars Intermedia in the Eel
58. Methotrexate treatment of psoriatic arthritis
59. Psoriatic arthritis: Clinical response and side effects to methotrexate therapy
60. Amethopterin (methotrexate) in connective tissue disease—Psoriasis and polyarthritis
61. A review of methotrexate therapy in Reiter syndrome
62. Favorable results using methotrexate in the treatment of patients with ankylosingspondylitis
63. Methotrexate therapy in juvenile rheumatoid arthritis: A retrospective study
64. Low-dose methotrexate in systemic onset juvenile chronic arthritis
65. Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype
66. Safety and efficacy of methotrexate therapy for juvenile rheumatoid arthritis
67. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis
68. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial
69. Diagnosis and treatment of systemic lupus erythematosus
70. Management of discoid and systemic lupus erythematosus
71. The use of methotrexate in steroid-resistant systemic lupus erythematosus
72. Methotrexate in the treatment of systemic lupus erythematosus
73. Reply
74. Methertrexate therapy for severe systemic lupus erythematosus
75. Low dose methotrexate treatment in systemic sclerosis
76. Inhibition of osteoclastic bone resorption by mechanical stimulation in vitro
77. Methotrexate treatment of recalcitrant childhood dermatomyosilis
78. Treatment of dermatomyositis with methotrexate
79. Treatment of corticosteroid-resistant polymyositis with methotrexate
80. Methotrexate therapy in polymyositis
81. Polymyositis and dermatomyositis: Combined methotrexate and corticosteroid therapy
82. Extracorporeal photochemotherapy for the treatment of systemic lupus erythematosus. A Pilot study
83. Methotrexate in refractory skin disease in dermatomyositis
84. Methotrexate for corticosteroid-resistant polymyalgia rheumatica and giant cell arteritis
85. Risikoprofil von niedrigdosiertem Methotrexate in der Therapie der chronischen Polyarthritis
86. Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis
87. Eruption of nodulosis and vasculitis during methotrex ate therapy for rheumatoid arthritis
88. Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis. Possible efficacy of hydroxy-chloroquine on nodulosis
89. Methotrexate associated rheumatoid nodulosis—Improvement with addition of sulfasalazine
90. Central nervous system toxicity associated with weekly low-dose methotrexate treatment
91. Hematologic abnormalities during low dose methotrexate therapy for rheumatoid arthritis
92. Methotrexate induced pancytopenia—A regional survey
93. Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy
94. Folate supplementation in methotrexate-treated rheumatoid arthritis patients
95. Megaloblastic anaemia during methotrexate treatment for psoriasis
96. Methotrexate therapy in rheumatoid arthritis. A two year prospective follow-up
97. The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment
98. Psoriasisliver-methotrexate interactions
99. Methotrexate induced liver cirrhosis—Studies including serial liver biopsies during continued treatment
100. Methotrexate-induced liver cirrhosis
101. Liver histology in patients receiving low dose pulse methotrexate for the treatment of rheumatoid arthritis
102. Liver biopsy findings in patients with rheumatoid arthritis undergoing longterm treatment with methotrexate
103. Histopathologic findings in the liver of rheumatoid arthritis patients treated with long-term bolus methotrexate
104. A prospective analysis of liver biopsies in rheumatoid arthritis patients receiving long term methotrexate therapy
105. Liver biopsies in methotrexate-treated rheumatoid arthritis patients: A 10 year experience
106. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy
107. Methotrexate-associated hepatotoxicity: Retrospective analysis of 210 patients with rheumatoid arthritis
108. Prospective study of hepatotoxicity in patients receiving methotrexate for rheumatoid arthritis
109. The effects of cyclosporin a on eicosanoid excretion in patients with rheumatoid arthritis
110. Liver Enzyme Levels in Arthritis Patients Treated with Long-Term Bolus Methotrexate
111. Clinical liver disease in patients with rheumatoid arthritis taking methotrexate
112. Acute, reversible hepatic failure associated with methotrexate treatment of rheumatoid arthritis
113. Hepatitis with bridging fibrosis and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking methotrexate
114. Methotrexate-induced asthma
115. Methotrexate-induced pneumonitis
116. Benefits and adverse drug experiences during long-term methotrexate treatment of 248 patients
117. Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis
118. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature.
119. Pulmonary toxicity following chronic methotrexate therapy for rheumatoid arthritis
120. Successful reintroduction of methotrexate after pneumonitis in two patients with rheumatoid arthritis
121. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: Report of five cases and review of published reports
122. Methotrexate pneumonitis after low-dose therapy for rheumatoid arthritis
123. Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis
124. Use of bronchoalveolar lavage in the evaluation of methotrexate lung disease
125. Methotrexate pneumonitis. Bronchoalveolar lavage findings suggest an immunologic disorder
126. Delayed methotrexate pneumonitis in rheumatoid arthritis
127. Rheumatois arthritis, methotrexate therapy, and pneumoeystis pneumonia
128. Bronchoalveolar lavage fluid evaluation in rheumatoid arthritis
129. Lung biopsy in rheumatoid arthritis
130. Methotrexate pneumonitis in rheumatoid arthritis—A dramatic response to treatment
131. Pneumoeystis carinii pneumonia following methotrexate therapy for rheumatoid arthritis
132. Nocardiosis associated with low dose methotrexate for rheumatoid arthritis
133. Pneumoeystis carinii pneumonia associated with methotrexate therapy in rheumatoid arthritis
134. Nocardia asteroides pneumonia complicating low dose methotrexate treatment of refractory rheumatoid arthritis
135. Pneumoeystis carinii pneumonia complicating low dose methotrexate treatment for psoriatic arthropathy
136. Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate
137. Increased risk of infection in patients treated with MTX
138. Increased infection rate in methotrexate treated patients with rheumatoid arthritis
139. Infection in rheumatoid arthritis
140. Toxicity to methotrexate in rheumatoid arthritis
141. Cryptococcosis associated with low-dose methotrexate for arthritis
142. Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate
143. Should methotrexate be discontinued before elective orthopedic surgery in patients with rheumatoid arthritis?
144. Methotrexate increases risk of post-surgical complications in rheumatoid arthritis patients
145. Methotrexate used for psoriasis and the risk of nonculaneous or cutaneous malignancy
146. No increase in second tumors after cytotoxic chemotherapy for gestationaltrophoblastic tumors
147. Is metho trexate therapy for psoriasis carcinogenic? A modified retrospective-prospective analysis
148. Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. A preliminary study
149. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate
150. Complications of immunosuppression associated with weekly low dose methotrexate
151. Associa tion of methotrexate, rheumatoid arthritis and lymphoma Report of 2 cases and literature review
152. Hepatocellular carcinoma in a patient with psoriasis and methotrexateinduced cirrhosis
153. Primitive neuroectodermal tumor presenting as a delayed sequela to cranial irradiation and intratecal methotrexate
154. Renal function in methotrexate treated psoriatics
155. The effect of age on methotrexate efficacy and toxicity
156. Kidney biopsies in methotrexate-treated psoriatics
157. Long-Term Prospective Study of the Use of Methotrexate in the Treatment of Rheumatoid Arthritis
158. The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man
159. Renal function and the rate of disappearance of methotrcx ate from serum
160. Drug-drug interactions with antirheumatic agents: Review of selected clinically important interactions
161. Drug interactions with methotrexate
162. Pancytopenia from using trimetoprime and methotrexate
163. Effect of aspirin and sulindac on methotrexate clearance
164. Methotrexate in Older Patients with Rheumatoid Arthritis
165. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis
166. The relationship of preexisting lung disease to the occurrence of methotrexate pneumonitis in rheumatoid arthritis patients
167. The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients
168. Basic calcium phosphate crystals stimulate cell proliferation and collagenase message accumulation in cultured adult articular chondrocytes
169. Long-Term Prospective Study of Methotrexate in the Treatment of Rheumatoid Arthritis
170. Administration of folic acid after low dose methotrexate in patients with rheumatoid arthritis
171. Low dose methotrexate with leucovorin rescue in the management of rheumatoid arthritis
172. Concurrent use of folinic acid and methorexate in rheumatoid arthritis
173. Acute and chronic effects of methotrexate on hepatic, pulmonary, and skeletal systems